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Abstract 
Neutrophils play a major role in inflammation by releasing large amounts of reactive 
oxygen species (ROS) produced by NADPH oxidase (NOX) and myeloperoxidase (MPO). 
This ROS overproduction is mediated by phosphorylation of the NOX subunits with an 
uncontrolled manner. Therefore, targeting neutrophil subunits would represent a promising 
strategy to moderate NOX activity, lower ROS, and other inflammatory agents, such as 
cytokines and leukotrienes, produced by neutrophils. For this purpose, we investigated the 
effects of protectin DX (PDX) - a docosahexaenoic acid (DHA) di-hydroxylated product 
which inhibits blood platelet aggregation - on neutrophil activation in vitro. We found that 
PDX decreases ROS production, inhibits NOX activation and MPO release from neutrophils. 
We also confirm, that PDX is an anti-aggregatory and anti-inflammatory agent by inhibiting 
both cyclooxygenase-1 and -2 (COX-1 and COX-2, E.C. 1.14.99.1) as well as COX-2 in 
lipopolysaccharides (LPS)-treated human neutrophils. However, PDX has no effect on the 5-
lipoxygenase pathway that produces the chemotactic agent leukotriene B4 (LTB4). Taken 
together, our results suggest that PDX could be a protective agent against neutrophil invasion 
in chronic inflammatory diseases. 
 
Keywords 
Human neutrophils; inflammation; protectin DX; NADPH oxidase; ROS-derived oxidative 
stress 
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Introduction 
Chronic inflammation is involved in various diseases including atherosclerosis [1], bowel 
disease [2, 3], cancer [4], cardiovascular diseases [5], the metabolic syndrome [6], and 
rheumatoid arthritis [7]. They all have in common [8] excessive production of pro-
inflammatory mediators such as interleukin (IL)-1, IL-6, IL-8 [9], granulocyte macrophage-
colony stimulating factor (GM-CSF) [10], leukotriene B4 (LTB4), platelet-activating factor 
(PAF), and tumor necrosis factor-α (TNF-α) [8]. Highly activated inflammatory cells such as 
neutrophils, monocytes and macrophages [11], and production of reactive oxygen species 
(ROS) [12–15] are common features. A major source of ROS at inflammation sites is the 
reduction of an oxygen molecule to superoxide anion (O2
–.
) by neutrophil enzyme complex 
NADPH oxidase (NOX) [16], and hypochloric acid (HOCl) produced by myeloperoxidase 
(MPO) from hydrogen peroxide [13]. In physiological situations, NOX activation in 
neutrophils is tightly regulated to avoid tissue damage. However, a dysregulation occurs in 
chronic inflammatory states where NOX subunits are strongly phosphorylated and 
translocated to cell plasma membrane, resulting in highly active oxidase overproducing ROS 
[17]. Targeting NOX subunits to decrease ROS overproduction would then represent a 
strategy to develop new anti-inflammatory approaches. Dietary manipulation is a possible 
way to prevent inflammatory diseases that involve polymorphonuclear neutrophil (PMN) 
activation and oxidative stress. As a matter of fact, dietary long-chain n-3 polyunsaturated 
fatty acids (PUFA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, present in 
marine food, have been widely used. As an example, they have been shown to attenuate 
inflammation and neutrophil infiltration in an experimental model of colitis [18]. N-3 PUFA 
may be converted into active oxygenated derivatives named protectins and resolvins which 
may fight inflammation [19]. Moreover, conjugated double bond-containing PUFA, like 
conjugated linoleic (CLA) and linolenic (ClnA) acids have been reported to decrease the 
incidence of tumors in mice, to inhibit cell proliferation and invasion of cancer cells by 
promoting apoptosis [20–22]. We have previously found that punicic acid, a conjugated triene 
PUFA found in high percentage (70%) in pomegranate seed oil, exerts a potent anti-
inflammatory effect through inhibition of TNFα-induced priming of neutrophil NOX, by 
targeting the p38MAPK/Ser
345
-p47
phox
 axis, and by decreasing neutrophil degranulation and 
MPO release [23]. On the other hand, oral administration of punicic acid or pomegranate seed 
oil to rats inhibits trinitrobenzene sulfonic acid (TNBS)-induced colitis and decreases ROS-
induced tissue damage through a down regulation of neutrophil activation [23].  
4 
 
Recently, our group identified new di-oxygenated derivatives from PUFA, called 
poxytrins, which inhibit blood platelet aggregation [24]. Among them, protectin DX (PDX) 
deriving from DHA [25] shares some structure similarity with other conjugated triene fatty 
acids, like punicic acid and oleostearic acid. PDX is an isomer of protectin/neuroprotectin D1, 
which is known to have anti-inflammatory properties [19, 26]. More recently, PDX (called 
PD1 isomer, even PD1 through the paper) has been shown to inhibit the influenza virus 
replication [27], which makes it a relevant molecule to fight this infectious disease. The aim 
of the present study was to test whether PDX may have anti-inflammatory effect by 
modulating neutrophil activation. A second goal was to precise the anti-inflammatory 
potential of PDX through cyclooxygenase inhibition. We found that PDX decreases ROS 
produced by neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLF), and 
phorbol myristate acetate (PMA) in vitro, and partly inhibited neutrophil degranulation and 
MPO release by fMLF-triggered neutrophils. Also, PDX is an inhibitor of COX-1, as well as 
COX-2 which the activity is enhanced during inflammation, but fails to inhibit the 5-
lipoxygenase pathway. Altogether these effects provide evidence that PDX may be an anti-
inflammatory agent acting through original mechanisms.  
 
Materials and Methods 
 
Reagents and antibodies 
 
PMA, fMLF, protease and phosphatase inhibitors, DHA, arachidonic acid (ARA), soybean 
lipoxygenase (sLOX) (E.C. 1.13.11.12, Type 1-B), COX-1 from sheep, and human 
recombinant COX-2 (E.C. 1.14.99.1), N,O-Bis(trimethylsilyl)-trifluoroacetamide (BSTFA) 
were from Sigma-Aldrich (St Quentin Fallavier, France). Endotoxin-free buffers and salt 
solutions were from Invitrogen/Life Technologies SAS (St Aubin, France). Anti phospho-
Ser
345
-p47
phox
 and anti-p47
phox
 were from Cell Signaling/Ozyme (St Quentin Yvelines, 
France). Anti MPO antibody was from Abcam. Organic solvents were from Carlo-Erba. All 
chemicals used were reagent grade or with the highest quality available. [
3
H]-ARA (6.6 x 10
9
 
Bq/mM) was from Perkin Elmer, USA. 
 
PDX synthesis 
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PDX was prepared as previously described [25]. Briefly, 200 µM DHA was incubated with 
soybean lipoxygenase in sodium-borate buffer (pH 9.0) on ice for 30 min, synthesized 
hydroperoxides were then reduced by NaBH4 for 15 min, and the reduction step was stopped 
by adding acetic acid to pH 3.0. PDX was extracted by using a C18-Sep Pak cartridge, 
collected by reverse phase high performance liquid chromatography (RP-HPLC), and 
measured according to its UV absorbance.  
 
Preparation of human neutrophils and measurement of ROS production 
 
Human neutrophils were obtained from healthy donors, in using LPS-free conditions by one-
step purification on polymorphprep dextran sedimentation as previously described [28]. 
Briefly, freshly drawn blood was added to cold dextran solution (0.1 mM dextran T500, 40 
mM EDTA, 120 mM NaCl, pH 7.4) in a screw-cap polypropylene tubes, and mixed gently. 
After at least 1 hour on melting ice, the upper solution was collected and mixed with 
phosphate-buffered saline (PBS) pH 7.4. Cold Ficoll (density 1.077) was added carefully to 
the bottom of the tubes and were further centrifuged at 500 g for 20 min at 4°C. After 
centrifugation, lymphocytes were removed and the pellets were re-suspended in cold PBS. 
Red cells were lysed by hypotonic shock. Neutrophils were then washed twice with PBS and 
kept on ice until analysis.  
ROS production was measured with a luminol-amplified chemiluminescence method: 
human neutrophils were suspended in Hank’s balanced salt solution (HBSS) containing 10 
µM luminol, and pre-heated at 37°C in the thermostated chamber of the luminometer 
(Berthold-Biolumat LB937) prior to treatment with PDX. Neutrophils were then stimulated 
with PMA (0.162 mM) or 0.1
 
µM fMLF, for chemiluminescence recording. 
 
Measurement of released MPO from neutrophils 
 
The release of MPO was performed by measuring its activity in using the H2O2-dependent 
tetramethyl benzidine (TMB)-oxidation assay at 650 nm. Human neutrophils were suspended 
in HBSS and pre-heated at 37
 °
C. The cells were treated with PDX, and then stimulated or not 
with 0.1 µM fMLF. Neutrophils were then centrifuged and MPO activity was measured in 
supernatants. Total MPO activity has been expressed in mU/min relative to a standard curve 
established with known amounts of triton X-100-treated neutrophils. 
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Immunoblotting of MPO released by fMLF stimulated neutrophils was done with primary 
rabbit antibodies against MPO (dilution: 1/10,000), and with a horseradish peroxidase (HRP)-
labeled-goat anti-rabbit antibody (dilution: 1/10,000). The reaction was measured by using 
enhanced chemiluminescence (ECL) reagents. 
 
Detection of Ser
345
 phosphorylation in neutrophils 
 
Neutrophils were incubated with different concentrations of PDX for 20 min, then treated with 
0.1 µM fMLF for 20 min. Cell proteins were denatured in Laemmli buffer [29]. The samples 
were analyzed by 10% SDS-polyacrylamide gel electrophoresis (PAGE), and immunoblotting 
was done with primary rabbit antibodies against phospho-Ser
345
 (dilution: 1/10,000) or against 
p47
phox
 (dilution: 1/5,000), then with HRP-labeled-goat anti-rabbit antibody (dilution: 
1/10,000). The reaction was measured by using ECL reagents. 
 
Measurement of 5-lipoxygenase activity in neutrophils 
 
Human neutrophils, suspended in a Tyrode-HEPES buffer containing 2 mM of Ca
2+
, were 
pre-incubated with 1µM PDX for 3 min at 37°C, and were then triggered with 1 µM of 
ionophore A23187 plus 10 µM of ARA for 10 min. The reaction was terminated by acidifying 
the media to pH 3.0 with acetic acid. Oxygenated metabolites (5-hydroxy-6E,8Z,11Z,14Z-
eicosatetraenoic acid (5-HETE), LTB4 and its isomers) were then extracted by solid phase 
extraction on Sep-Pak C18-cartridges. They were analyzed by RP-HPLC on a Waters 
XBridge C18 column (4.6×250 mm, 3.5 µm) by using a linear solvent gradient (1 mL/min): 
solvent A was acetonitrile/water (10:90, v/v) pH 3.0, and solvent B was acetonitrile. Mono-
hydroxylated conjugated diene and di-hydroxylated conjugated triene fatty acids were 
detected with a diode array detector at 235 nm and 270 nm, respectively.  
 
GC-MS measurement of COX-1 and COX-2 activities 
 
Commercial COX-1 and COX-2 were pre-incubated for 15 min in a 0.1 M Tris HCl buffer pH 
8.0 with or without 0.5 or 5 µM of PDX, and incubated with 10 µM ARA as a substrate for 10 
min. Albumin (45 g/L) was added to enhance the formation of prostaglandin (PG) D2 and E2 
from PGH2 at the end of incubation [30]. Reaction was stopped by acidification to pH 3.0 
with acetic acid. PGD2 and E2 were then extracted by 10 volumes of diethyl ether. Deuterated 
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PGD2 and E2 were used as internal standards for their quantification. Prostaglandins were 
derivatized into methoxime, pentafluorobenzyl ester and trimethysilyl ether, and further 
analyzed by NICI GC-MS. Selected ions corresponding to [M-181]
-
 (loss of the PFB group): 
m/z: 524 for both derivatized PGD2 and E2 and m/z: 528 for their corresponding deuterated 
internal standards, were used for their measurement.   
 
Measurement of LPS-induced COX activities in human neutrophils  
 
Human neutrophils were treated by LPS (100 ng/mL) in order to overexpress COX-2. After 4 
hours, cells were pre-incubated in presence or absence of 10 µM PDX for 3 min at 37°C, and 
10 µM radiolabelled ARA (333 Bq/nmol) was added as a substrate for 10 min. After 
acidification to pH 3.0 with acetic acid, lipids were extracted by 10 volumes of diethyl ether 
and separated by thin-layer chromatography (TLC). Radioactivity of extracted gel spots 
corresponding to PGD2 and E2 were measured by scintillation counting. 
 
PDX incorporation into neutrophils 
 
10 µM PDX was incubated with isolated neutrophils for 3 min at 37°C. Cells were washed 
twice with buffer containing 45 g/L fatty acid free albumin. After centrifugation at 500 g for 
20 min at 4°C, pellets were extracted using methanol/acidified water and PDX was measured 
by LC-MS/MS (AB Sciex, Qtrap 4500), using the double 15-lipoxygenase product of 
arachidonic acid (8,15-diHETE) as an internal standard. Quantification was done using 
multiple reaction monitoring mode (MRM). Parent ions were m/z: 359 and m/z: 335 and 
daughter ions m/z 153 and m/z 235 for PDX and 8,15-diHETE respectively.  
  
Statistical analysis 
 
All results are expressed as means ± standard error of the mean (SEM) or means ± standard 
deviation (SD). One away ANOVA followed by Fisher’s protected least significant difference 
(PLSD) post hoc test was used to assess differences between groups. P-value of 0.05 was 
assumed to represent the level of significance. Statistical significance was determined by 
using 2-tailed Student’s t tests in case of comparison between two groups of values. 
 
8 
 
Results  
 
PDX inhibits fMLF and PMA-induced superoxide anion from neutrophils 
 
PDX was tested on ROS production in response to PMA. In presence of PDX for 20 min, 
PMA-induced neutophil production of ROS was decreased. Our results (Fig. 1) show that in 
absence of PDX, PMA induced a marked ROS production compared to baseline (Fig. 1A), 
and incubation of neutrophils with PDX prior to the addition of PMA, induced a significant 
decrease in ROS production (Fig. 1B), indicating that PDX inhibited NOX activity, and/or 
scavenged the produced ROS. The effect of PDX was dose-dependent from 2.5 µM to 10 µM. 
At these concentrations, PDX did not affect PMN viability as determined by trypan blue 
exclusion test (not shown).  
We then analyzed the effect of PDX on the neutrophil respiratory burst induced by 0.1
 
µM 
fMLF. Figure 2A shows that, similarly to the PMA experiments, the luminescence of 
neutrophils stimulated with fMLF is increased and lowered by PDX, in a dose-dependent 
manner, also from 2.5 µM to 10 µM (Fig. 2B). In contrast, PDX had no effect on superoxide 
production by the in vitro xanthine/xanthine oxidase system, and had no effect on H2O2 
availability as measured by the peroxidase-catalyzed reaction (data not shown). These data 
suggest that PDX did neither scavenge superoxide anion, nor H2O2. 
 
PDX inhibits fMLF-induced MPO release from neutrophils 
 
Neutrophil NOX produces superoxide anion (O2
-
) that is the source of other ROS. O2
-
 is 
spontaneously dismutated into H2O2 at acidic pH, within the phagosome or the extracellular 
medium. The release of MPO catalyzes the conversion of H2O2 into the toxic molecule HOCl 
in presence of chloride ions [31–33]. Also, reaction between H2O2 and OCl
- 
produces
 
singlet 
oxygen, another reactive oxygen species.
 
Therefore, the activation of NOX synergizes with 
MPO for inflammatory processes. The effect of PDX was then investigated on neutrophil 
release of MPO. Human neutrophils were incubated in HBSS medium in presence or absence 
of PDX for 20 min at 37°C. After washing and centrifugation, PMN were stimulated with 0.1
 
µM fMLF, and MPO release was assessed by measuring its activity in supernatant of all 
samples. Figure 3A shows that MPO activity from neutrophils pre-treated with PDX and 
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stimulated with 0.1 µM fMLF, was significantly decreased in a dose-dependent manner as 
compared to control (neutrophils treated without PDX, but stimulated with fMLF). To test 
whether this inhibitory effect may reflect decreased neutrophil degranulation, or is related to 
decreased enzymatic activity, we performed a western blot analysis of the supernatant from 
fMLF-stimulated samples, using an antibody directed against human MPO. Results (Fig. 3B) 
show that the amount of MPO was lower in 5 µM  and 10 µM PDX-treated neutrophils than 
in control (neutrophils treated without PDX, but stimulated with fMLF), whereas we did not 
find any effect of PDX on the enzymatic activity determined in vitro on recombinant MPO 
activity (data not shown). Taken together our results suggest that PDX exerts an inhibitory 
effect on stimulated neutrophil oxidative burst and degranulation. 
 
PDX inhibits fMLF-induced p47
phox
 phosphorylation on Ser
345
 
 
We have previously shown that production of ROS by NOX results from the phosphorylation 
of its cytosolic subunits, particularly p47
phox
 on Ser
345
. The effect of PDX on this process is 
shown in Fig. 4. The level of phosphorylated 
345
P-Ser on p47
phox
 has been corrected from the 
amount of total p47
phox
, which shows that PDX significantly lowers the phosphorylation of 
this protein when induced by fMLF treatment of neutrophils (Fig. 4A and B). 
 
Effect of PDX on COX-1 and COX-2 activities 
 
The inhibition of purified cyclooxygenases (COX-1 and COX-2) by 0.5 µM and 5 µM of 
PDX were assessed by GC-MS measurement of both PGD2 and E2 which represent the global 
prostaglandin synthesis after albumin addition and acidification that convert PGH2 into PGD2 
and E2 (see methods). Results reported in Table 1 show that 0.5 µM and 5 µM PDX 
significantly decreased prostaglandin production through COX-1 by around 55% and 75%, 
respectively. Interestingly, the inhibition of COX-2 by PDX seems even more efficient as the 
decreased prostaglandin production through COX-2 attained 70% and 80% in response to 0.5 
µM and 5 µM PDX, respectively. This means that the decreased production of pro-
inflammatory prostaglandins by PDX may substantially contribute in its anti-inflammatory 
effects. 
 
10 
 
Effect of PDX on prostaglandin production in human neutrophils treated by LPS 
 
Neutrophils were treated by LPS in order to overexpress COX-2. Radiolabelled ARA was 
then used as a substrate for the neutrophil cyclooxygenase in the presence or absence of 10 
µM PDX, in order to exclude the contribution of released endogenous ARA in response to 
LPS. COX activity was assessed by measuring the radioactive PGD2 and E2 as representatives 
of prostaglandin production. Results (Fig. 5) show that such a production was enhanced by 
121% following the LPS treatment, compared to non-stimulated cells, reflecting the expected 
COX-2 overexpression. 10 µM PDX significantly decreased prostaglandin production by 
around 25% in LPS-treated neutrophils. The inhibition by PDX was not visible in non-treated 
neutrophils compared to control (not shown). 
 
Effect of PDX on 5-lipoxygenase activity in activated human isolated PMN 
 
The 5-lipoxygenase pathway is a relevant one to promote inflammation through the ARA 
metabolite LTB4. The 5-LOX end-products are LTB4 and its geometrical and stereochemical 
isomers (LTB4 isomers), as well as 5-HETE. Measuring all those end-products provides a 
global view of the 5-lipoxygenase pathway acting upon ARA. Results summarized in Table 2 
show that even at 10 µM, PDX did not inhibit the 5-lipoxygenase pathway, meaning that the 
inhibition of the cyclooxygenase reported above is rather specific. 
 
PDX incorporation into neutrophils 
 
The IC50 for the inhibition of isolated COX enzymes by PDX being much lower (less than 0.5 
µM) than in neutrophils (more than 10µM), studies on the uptake of PDX has been done.  
Incubation of neutrophils with 10 µM PDX led to low incorporation (8.5 +/- 0.7 %) as 
measured by LC-MS/MS. No degradation products were detected, and the remaining PDX 
(not incorporated) was measured in the supernatant fraction. 
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Discussion 
 
The present study shows that PDX inhibits both ROS production and MPO release by human 
neutrophils. Also, the inhibition of fMLF-induced activation of NOX results from the 
inhibition of the phosphorylation of p47phox on Ser
345
. 
Several cytokines, including TNF-, are involved in many inflammatory states. As a 
matter of fact, anti-TNF- antibodies are used to treat some severe forms of inflammatory 
bowel disease [34]. This cytokine primes the neutrophil ROS production that is a key process 
in inflammation [35]. Primed neutrophils have been reported in diverse inflammatory states 
[36, 37]. One molecular mechanism involved in this priming process is the phosphorylation of 
p47
phox
 on Ser
345
. Anti-inflammatory interventions could use nutritional approaches to 
decrease such a phosphorylation and subsequently ROS overproduction, without altering that 
one which is required for innate immunity and host defence. The present study shows that 
PDX, a double lipoxygenase product of DHA, is able to slow-down NOX activation and 
subsequent ROS-derived oxidative stress. MPO activity was also decreased by PDX to the 
same extent. As MPO and ROS (especially H2O2) generate toxic molecules at the 
inflammatory sites, the inhibition by PDX supports the potential action of this DHA 
metabolite as an anti-inflammatory agent. However, this protective effect needs to be 
confirmed in vivo.  
Other fatty acids may affect ROS production in neutrophils. Linoleic acid (LA), the main 
consumed fatty acid in western countries [38], may act synergistically with TNF-α to affect 
ROS production [39, 40]. The LA product ARA can directly activate neutrophils [41] through 
enzymatic conversion into pro-inflammatory oxygenated metabolites such as LTB4 and PGE2 
[42–44]. By contrast, n-3 PUFA such as EPA and DHA, provided by marine lipids, are 
oxygenated into less inflammatory and even anti-inflammatory derivatives counteracting the 
effects of ARA-derived eicosanoids [45]. Indeed, Hardy et al. have shown that pre-treatment 
with ARA, enhances fMLF- or PMA-stimulated neutrophils, then inducing more superoxide 
anion production than in non ARA-enriched cells [46]. In contrast, a recent study reported 
that EPA and DHA could increase the response of neutrophils to TNF-α [47]. None of these 
in vitro and in vivo experiments have addressed the molecular mechanism that might explain 
the increased ROS production. 
Nutritional doses of EPA and DHA have been used in humans to prevent inflammatory 
states, and to lower the level of circulating inflammation markers [45]. The inhibitory effect 
of PDX on prostaglandin synthesis by either sheep COX-1 or human recombinant COX-2 is 
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quite relevant in this respect, especially at 0.5 µM. This was also observed to a lesser extent in 
neutrophils treated by LPS. However, this inhibition is in the same order if we consider that 
only 8% of PDX was incorporated into the neutrophils after 10 µM incubation. This means 
that PDX would be more relevant when produced inside neutrophils through their own 15-
LOX. 
In addition to the COX-1 inhibition, already observed in relation with the inhibition of 
platelet aggregation [24], PDX appears to be an even more potent inhibitor of COX-2 which 
is the inducible enzyme, although detectable at low level in most normal tissues. It becomes 
abundant in activated macrophages and other cells at sites of inflammation. The anti-
inflammatory potential of PDX is quite specific since it fails to inhibit the 5-lipoxygenase 
pathway. Therefore, PDX appears to be an original anti-inflammatory agent to play a 
protective role in chronic inflammatory diseases. 
We conclude that PDX inhibits fMLF-induced ROS production by targeting the neutrophil 
p47
phox
/NOX axis and MPO release as well. Besides its inhibitory effects on platelet 
aggregation through inhibition of COX-1, that is confirmed against purified COX-1, PDX 
inhibits COX-2 and then could protect against inflammation. It might be used for the 
prevention and treatment of various inflammatory diseases. However, further in vivo studies 
are needed to confirm those in vitro findings.  
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Figure Legends 
 
Figure 1: Effect of PDX on PMA-induced superoxide anion production by human 
neutrophils.  
Human neutrophils (2 x 10
6
 cells/mL HBSS) were incubated in the absence or presence of 
different concentrations of PDX for 20 min. PMA (0.162 mM) was added, and O2
°
 production 
was measured by chemiluminescence technique in the presence of 10 µM luminol. One curve 
is representative of four experiments (A). Total chemiluminescence in each condition was 
quantified and presented as mean ± SEM of 4 experiments (B). Different letters indicate 
significant differences between the groups at p< 0.001 level (one way ANOVA followed by 
Fisher’s PLSD test).  
 
 
Figure 2: Effect of PDX on fMLF-induced superoxide anion production by human 
neutrophils.  
Human neutrophils (2 x 10
6
 cells/mL HBSS) were incubated in the absence or presence of 
different concentrations of PDX for 20 min. fMLF (0.1 µM) was added, and O2
°
 production 
was measured by chemiluminescence technique in the presence of 10 µM luminol. One curve 
is representative of four experiments (A). Total chemiluminescence in each condition was 
quantified and presented as mean ± SEM of 4 experiments (B). Different letters indicate 
significant differences between the groups at p< 0.005 level (one way ANOVA followed by 
Fisher’s PLSD test).  
 
Figure 3: Inhibitory effect of PDX on neutrophil release of MPO.  
Human neutrophils (2 x 10
6
 cells/mL HBSS) were pretreated or not (control) with 5 or 10 µM 
PDX for 20 min, then stimulated with fMLF (0.1 µM) for 3 min. Cells were centrifuged and 
MPO activity (A) was determined in the supernatants using H2O2 and TMB as described in 
Materials and Methods. Different letters indicate significant difference between groups at p< 
0.001 level. MPO protein (B) was determined by immunoblotting with anti MPO antibody. 
Data are presented as mean ± SEM of 4 experiments. Different letters indicate significant 
differences between the groups at p< 0.05 level (one way ANOVA followed by Fisher’s 
PLSD test).  
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Figure 4:  Effects of PDX on fMLF-induced p47
phox
 phosphorylation on Ser345. 
Human neutrophils (2 x 10
6
 cells/mL HBSS) were pretreated with 5 or 10 µM PDX for 20 
minutes, then incubated with or without (control) fMLF (0.1 µM) for 20 minutes. Cells were 
then lysed and proteins were analyzed with SDS-PAGE and immunoblotting with anti-
phospho-ser345 antibody (pSer345) or anti-p47phox antibody (p47
phox
) (A). Western blots 
from different experiments were scanned, phosphorylated and total p47
phox
 were quantified by 
densitometry, and the intensity of phosphorylated p47
phox
 was corrected for the amount of 
p47
phox
 (B). Data are representative of 3 independent experiments using cells from different 
healthy donors. Results are expressed as mean ± SD (n=3). Different letters indicate 
significant differences between the groups at p< 0.05 level. One away ANOVA followed by 
Fisher’s PLSD test.  
 
Figure 5:  Effect of PDX on the production of PGD2 and E2 in human neutrophils treated or 
not by LPS. 
Human neutrophils (2 x 10
6
 cells/mL HBSS) were treated in the presence or absence of 100 
ng/mL LPS for 4 hours. Cells were then pre-incubated with and without 10 µM PDX for 3 
min at 37°C and incubated with 10 µM radiolabelled ARA for 10 min. Lipids were extracted 
after acidification, and PGD2 and E2, representative of prostaglandin production, were 
separated by TLC. Their corresponding spots were detected by dichlorofluorescein, scrapped 
off and the radioactivity was counted. Results are expressed in nanomoles of PGD2 and E2 
synthesized and represent the mean ± SEM of 4 determinations. * p< 0.05 as compared to 
control. 
 
 
 
 
 
 
 
 
Table 1 Effect of PDX on COX activities  
 
 Control PDX 0.5 µM PDX 5 µM 
COX-1 3.4 ± 0.4 1.5 ± 0.04* 0.9±0.02* 
COX-2 1.6 ± 0.7 0.5 ± 0.02* 0.3±0.01* 
 
Each result is expressed in nanomoles of PGD2 + E2, representatives of total prostaglandin production (see 
methods). The results represent the mean ± SD of 3 determinations, *p< 0.05 as compared to control. 
 
Table 2 Effect of PDX on the 5-lipoxygenase in activated human neutrophils 
 
 Control PDX 1 µM PDX 10 µM 
LTB4s 9.0±1.6 9.0±3.0 9.1±2.4 
5-HETE 0.8±0.3 0.6±0.3 0.6±0.4 
 
Each result is expressed in nanomoles of the sum of the different 5-lipoxygenase metabolites: LTB4s (LTB4 + 
LTB4 isomers) and 5-HETE and represents the mean ± SD of 3 determinations. 
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